FIBRONEER™ trials for IPF, other progressive fibrosing ILDs FIBRONEER™ trials for IPF, other progressive fibrosing ILDs Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program
Boehringer Ingelheim enrolls first patient in Phase III trial of BI 1015550 in idiopathic pulmonary fibrosis Boehringer Ingelheim enrolls first patient in Phase III trial of BI 1015550 in idiopathic pulmonary fibrosis Boehringer Ingelheim enrolls first patient in Phase III trial of BI 1015550 in idiopathic pulmonary fibrosis
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases